MIT Chemists are Working on a Protein Fragment to Prevent Covid-19 from Entering the Human Lung Cells


MIT chemists have been carrying out research work in order to test a protein fragment for preventing the COVID-19 virus from entering human lung cells. Since the coronavirus pandemic has left the world in a miserable state, efforts are being made by different countries to develop a drug for this deadly virus. 

It is observed that a team of MIT scientists are now working to develop a potential drug, a short protein fragment, or peptide to mimic a protein present on the surface of human cells. According to the researchers, this new peptide will help to prevent the entry of coronavirus pandemic into human lungs. 

The work on this project was started by Pentelute’s lab in the beginning of the March month when the Cryo-EM structure of the coronavirus spike protein was unveiled. An effort is being made by a team of researchers to determine the necessary conditions for the interaction of a virus with human lung cells. And it will help in the development of a suitable drug for COVID-19 treatment. 

In different parts of the world, the sale of various types of peptides has increased for carrying out laboratory works. Due to this, a number of laboratories can easily buy melanotan 2 or other peptides from online sources. The availability of peptides for laboratory researches has increased over the last few years due to the spread of various infectious diseases. 

Across the globe, various types of research works are making efforts to seek treatments for COVID-19. And some of them are using peptide drugs on this subject. According to Pentelute lab, peptide drugs are easy to manufacture in large quantities and this is the biggest benefit of using these drugs. 

Nicole Stump

Nicole is a science graduate and professional with a strong experience in content management of Science related articles. Her strength includes the sound knowledge of science as well as astronomy.

Leave a Reply

Your email address will not be published. Required fields are marked *